Editorial Comment
Calcium Channel Blockers (n=383) were entered into the trial. Randomization produced satisfactorily matched groups, although there were more smokers (51% versus 39%) and fewer patients with three-vessel disease (15% versus 23%) in the control group than in the treated group. Clinical events, drop-out rates, plasma total cholesterol (=260 mg/dl), and high density lipoprotein cholesterol did not differ between groups. However, patients receiving nicardipine exhibited slightly lower systolic and diastolic arterial pressures. Arteriography after 2 years of treatment was repeated in 87% of the patients. Frames from the two cine angiograms were analyzed quantitatively using the video technique of Reiber et al.27 A total of 2,323 lesions, or 6.9 lesions per patient, was assessed in single optimal views. Using stenosis diameter changes of more than 0.4 mm as a criterion for a change in lesion severity, progression occurred in 10% and regression in 3.5% of the patients in both groups. A subgroup analysis was subsequently performed to determine a possible treatment effect on "early lesions," arbitrarily defined as lesions producing less than 20% stenosis in the initial arteriogram. Four hundred eleven such lesions were detected in 217 angiograms -178 lesions in 99 treated (1.80 lesions per patient) and 233 lesions in 118 untreated patients (1.96 lesions per patient). It is unclear whether the 217 patients with small lesions had on average significantly fewer or less-severe lesions overall compared with the remaining 166 patients. Using again a 0.4-mm-diameter change as a criterion, lesion progression occurred in 7.3% treated and 14.2% untreated patients (p<0.039 by two-sided test). In a stepwise logistic analysis, there appeared to be a marginally significant association between nicardipine effects on the progression of small lesions and arterial pressure measured 6 months after onset of therapy. No data are provided regarding possible associations at other time points (12, 18 , and 24 months). The authors are appropriately cautious in interpreting the statistical analysis. As a result of the composite analysis focusing first on severe and then on minor stenoses (more than 50% and less than 20%), we are provided little information about lesions with occlusions between 20% and 50%, a range that accounted for 40% of all lesions in another recent angiographic trial (CLAS). 28 The authors conclude that nicardipine had no effect on advanced coronary atherosclerosis but may retard the progression of small lesions. The validity of the conclusion rests on the objectivity of the subgroup analysis. The authors assure us that "the choice of a <20% occlusion as the definition for minimal lesions was made before reviewing the data" and that "the cutpoint of 20% was not chosen to maximize differences post hoc."
The study of Waters et a126 is similar in many respects to the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT).29 The IN-TACT study was a prospective, double-blind, placebo-controlled multicenter (n=9) trial in which patients with mild coronary disease were randomized to treatment with nifedipine (80 mg/day) or placebo. Standardized arteriography performed in 425 patients was repeated in 82% of the patients after a 3-year period. Blinded computer-assisted evaluation of the arteriograms was performed by the same technique (CAAS)27 as that used by Waters et al. The European researchers selected patients with mild coronary disease (lesions per patient was -3.5 compared with =7 in the Montreal study or =11 in the CLAS study)28 to assess the appearance of small lesions in coronary segments initially showing no lesions. Taking into consideration the inaccuracy of quantitative arteriography in the detection of small lesions, they accepted as "lesions" stenoses producing more than 20% luminal narrowing. Two-sided statistical tests indicated that treatment had significantly reduced the number of new lesions (p<0.034 by two-sided test). As in the Montreal study, an effect on the progression or regression of preestablished severe lesions was not demonstrable. In contrast to the Montreal study, arterial pressures in the treated and placebo groups were virtually identical. An interesting feature of the INTACT study was the frequency of total occlusions in initially normalappearing segments.29 In a small-scale prospective coronary angiographic study, Loaldi and collaborators30 compared the effects of treatment with nifedipine (39 patients), propranolol (36 patients), or isosorbide dinitrate (38 patients) on the progression of coronary disease. Angiograms obtained at the beginning and end of a 2-year treatment period were evaluated blindly by a computer-assisted quantitative method. The authors concluded that nifedipinetreated patients had developed significantly fewer new stenoses compared with the other two groups, but they underscored the desirability of a large-scale study. Based on encouraging retrospective data with verapamil, another prospective coronary arteriographic study in 444 patients with coronary artery bypass grafts has been initiated (Frankfurt Isoptin Progression Study, or FIPS).31 Another ongoing trial evaluates effects of isradipine on the progression of carotid disease in 800 hypertensive men monitored for 3 years by standardized ultrasound imaging (MI-DAS).32 In an ongoing trial evaluating effects of nifedipine (60 mg/day) on the patency of coronary bypass grafts, Gottlieb et 
